PPLPHARMA211.99

Piramal Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEGLANDWOCKPHARMAASTERDMCOHANCELALPATHLABNATCOPHARMMcap ₹28,134 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation740.6816.3831.2
+ Finance Costs448.5421.6340.8
+ Interest Income-11.9-10.4-5.2
+ Fair Value (Gains) / Losses4.8-7.1-12.2
+ Share-based Payments27.548.041.7
+ Unrealised FX (Gain) / Loss48.331.6184.3
+ Other Non-cash Items22.172.6188.8
Changes in Working Capital
+ Inventories-531.8-197.1-798.1
+ Trade Receivables — Current-391.4-233.5217.2
+ Other Financial Assets — Current18.9-26.4-22.7
+ Other Financial Assets — Non-current0.70.1-19.6
+ Other Current Assets20.8-36.56.6
+ Other Non-current Assets2.4-7.213.8
+ Trade Payables — Current404.318.2778.0
+ Other Financial Liabilities — Current29.874.812.4
+ Other Financial Liabilities — Non-current-5.00.00.0
+ Other Current Liabilities183.2-108.3314.4
+ Other Non-current Liabilities22.720.8-7.9
+ Provisions — Current4.4-0.7-0.6
+ Provisions — Non-current6.88.133.0
Cash from Operating Activities
Profit Before Tax (per I/S)119.8341.7-233.3-162.7
+ Total Adjustments (incl. Working Capital)1,045.4885.02,096.0
Cash from Operations (pre-tax)1,165.21,226.71,862.7
+ Other Inflows / (Outflows) — Operating-3.80.00.0
+ Income Taxes Paid156.8334.4210.2
Cash from Operating Activities1,004.5892.31,652.6
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)712.0664.4890.0
+ Disp of Fixed Assets1.65.313.4
+ Disp of Other Long-term Assets0.00.02.2
+ Purchase of Investments (Equity / Debt)1,670.71,872.4991.7
+ Sale of Investments (Equity / Debt)1,943.11,999.5887.9
+ Dividends Received — Investing22.146.337.7
+ Interest Received — Investing0.00.05.6
+ Other Inflows / (Outflows) — Investing-18.08.3108.7
Cash from Investing Activities-434.0-477.5-826.0
Cash from Financing Activities
+ Proceeds from Issue of Shares1,050.00.00.0
+ Proceeds from Exercise of Stock Options0.00.02.8
+ Buyback / Redemption of Own Shares14.10.00.0
+ Proceeds from Borrowings1,660.74,659.91,887.4
+ Repayment of Borrowings2,632.24,611.21,567.0
+ Payment of Lease Liabilities24.936.747.3
+ Interest Paid0.0438.4296.4
+ Dividends Paid0.014.518.6
+ Other Inflows / (Outflows) — Financing-461.80.00.0
Cash from Financing Activities-422.4-440.8-39.0
Net Changes in Cash (pre-FX)148.2-26.0787.6
+ Effect of FX Rate Changes on Cash17.8-10.96.4
Net Changes in Cash166.0-36.9793.9
Closing Cash219.2
Reference Items
EBITDA1,196.31,444.8921.61,010.1
EBITDA Margin %14.6415.7910.3910.97
Free Cash Flow (CFO − Capex)292.5227.9762.6762.6
Free Cash Flow to Equity-49.11,241.4
Free Cash Flow per Basic Share2.201.725.755.75
Price to Free Cash Flow36.89
Cash Flow to Net Income56.379.79-5.07
Cash Paid for Taxes156.8334.4210.2
Cash Paid for Interest0.0438.4296.4
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.